In Conversation with Kaela: How Research Gave a Mom of Two a Second Chance at Life
Kaela Graham-Bowman’s story reached national audiences this year when she was featured on 60 Minutes Australia. An Afghanistan veteran and nurse, Kaela was diagnosed with synovial sarcoma in 2020 at age 28, while working as an oncology nurse herself. What followed was a six-year fight through surgery, chemotherapy, a devastating relapse, and eventually a groundbreaking treatment that gave her and her two kids a future she wasn’t sure she’d have.
Kaela became the first Australian to access Tecelra (afamitresgene autoleucel), an engineered T-cell therapy built specifically to target synovial sarcoma cells. After her cancer returned and spread to both lungs in 2022, a moment she has described as feeling like her life was over, she exhausted every treatment available to her at home before traveling to the US for the roughly $2 million therapy, supported by Australia’s Medical Treatment Overseas Program. The results have been striking: scans have shown one tumor shrink from 7cm to 1cm and another from 4cm to 1cm, with a third holding stable and no disease detected elsewhere.
Julie Kramer, our Community Engagement and Partnerships Manager at SSF, sat down with Kaela to go beyond the headlines and talk about what that journey actually looked like, and what she wants other patients to take from it.
Pictures: news.com.au
A Diagnosis No One Expected
Kaela’s path to diagnosis started with pain in her thigh that she initially put down to an old army injury. A GP sent her for an ultrasound, and one doctor’s instinct changed everything.
“One of the doctors had seen a sarcoma before. And she was like, we need to rule out sarcoma. And I was just like, what’s that?”
Even as a working oncology nurse, Kaela had never encountered synovial sarcoma before. By the time she was diagnosed, the tumor was already wrapping around her femoral artery, forcing surgeons to perform an emergency full resection mid-biopsy. Chemotherapy started within a month, and she credits staying in her nursing job through treatment with keeping her going, telling 60 Minutes that losing her sense of purpose would have meant losing the fight.
Why Research Made the Difference
Kaela is candid about what saved her life: research. Without it, she believes she wouldn’t be here.
“Without TECELRA, without the research, I truly, in my heart, think I would be gone now. TECELRA is the first really promising thing for synovial sarcoma that we’ve had in so long. And there’s not enough research because there’s not enough funding.”
That’s the heart of what makes Kaela’s story so important to share. Synovial sarcoma is rare, aggressive, and chronically underfunded compared to more common cancers, which means every trial, every approved therapy, and every treatment breakthrough exists because patients before her chose to participate in research. Kaela didn’t just benefit from that system; she’s now part of it. She’s donated her own tumor tissue to the SSF Synovial Sarcoma Registry & Biorepository, turning the disease that nearly killed her into a resource that could help researchers find answers for the next patient.
“As ugly as it is, like this whole process, the whole disease, it’s so exciting being part of something like that. If I’m going to die, the least I can do is provide what’s trying to kill me to research so that someone else doesn’t have to go through that.”
Advocate for Yourself
Kaela’s clinical background gave her the confidence to push back, ask for second opinions, and refuse to be written off as a statistic, something she believes every patient deserves the tools to do, regardless of medical background.
“Advocate for yourself. If you don’t know how to advocate or what to ask, look it up… know that you can have a second opinion. And if your gut is telling you that something’s not right, believe it and question it. Advocacy for yourself is the most powerful thing you can have.”
Watch Kaela’s Story
Kaela’s full story aired on 60 Minutes Australia. Watch it here: Pioneering treatment for the rarest of cancers gives hope for terminal patients
Join Kaela in Advancing Research
Kaela has donated her own tumor tissue to the Synovial Sarcoma Registry & Biorepository, a first-of-its-kind initiative funded by SSF and housed at Children’s Hospital of Philadelphia in partnership with Penn Medicine. It’s the reason treatments like the one that saved her life exist, and every new participant helps bring the next one closer.
You can be part of what comes next. Join Kaela and enroll in the SSF Registry & Biorepository.
Enroll in the Registry & Biorepository →
Questions? Email SynovialSarcomaRegistry@chop.edu or call +1 267-827-8145.
Readers can find the full news.com.au feature on Kaela’s journey here: ‘Game-changing’ treatment giving hope for 35yo mum after terminal cancer diagnosis.
